We are live on
!
Find out more
SCM
Sarissa Capital Management Portfolio holdings
AUM
$158M
1-Year Est. Return
103.7%
This Fund
S&P 500
This Quarter
Est. Return
+2.79%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$432M
AUM Growth
+$41.5M
(+11%)
Cap. Flow
+$33.4M
Cap. Flow
% of AUM
7.73%
Top 10 Holdings %
Top 10 Hldgs %
99.98%
Holding
12
New
1
Increased
3
Reduced
2
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$36.3M |
| 2 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$27.3M |
| 3 |
Ironwood Pharmaceuticals
IRWD
|
+$25.6M |
| 4 |
AGN
Allergan plc
AGN
|
+$14.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
+$62.8M |
| 2 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$6.55M |
| 3 |
AbbVie
ABBV
|
+$989K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$30B
| $113M | 26.22% |
413,858
| – | – |
|
|
MDCO
2
DELISTED
Medicines Co
MDCO
| $63.3M | 14.65% |
1,922,000
| – | – |
|
3
Innoviva
INVA
$1.55B
| $61M | 14.12% |
3,660,705
| – | – |
|
|
AGN
4
DELISTED
Allergan plc
AGN
| $57.9M | 13.4% |
344,000
+86,700
| +34% | +$14.5M |
|
|
5
Ironwood Pharmaceuticals
IRWD
$696M
| $52M | 12.02% |
4,020,317
+2,050,217
| +104% | +$25.6M |
|
|
SHPG
6
DELISTED
Shire pic
SHPG
| $39.4M | 9.13% |
+264,000
| New | +$36.3M |
|
|
ICPT
7
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $39.1M | 9.04% |
635,300
+453,000
| +248% | +$27.3M |
|
|
NVLN
8
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $3.59M | 0.83% |
1,025,000
| – | – |
|
|
ACHN
9
DELISTED
Achillion Pharmaceuticals
ACHN
| $1.85M | 0.43% |
500,000
-2,000,000
| -80% | -$6.55M |
|
|
SEEL
10
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $587K | 0.14% |
13
| – | – |
|
|
11
AbbVie
ABBV
$443B
| $94K | 0.02% |
1,000
-9,000
| -90% | -$989K |
|
|
BIVV
12
DELISTED
Bioverativ Inc. Common Stock
BIVV
| – | – |
-1,165,000
| Closed | -$62.8M |
|
Similar funds
4A
DAM
PCP
CF
HEM
SF
AC
EP
Sarissa Capital Management's Q1 2018 Portfolio in Review
As of Q1 2018, Sarissa Capital Management held 12 positions worth $432M, up 11% from $391M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Sarissa Capital Management deployed $33.4M of net new capital in Q1 2018, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Shire pic: 264,000 shares worth $39.4M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 87% a quarter earlier.
On the sell side, the largest reduction was Achillion Pharmaceuticals, an estimated $6.55M trimmed.
- Sarissa Capital Management's largest Q1 2018 buy was Shire pic: 264,000 shares worth $39.4M.
- Sarissa Capital Management added most to Intercept Pharmaceuticals, Inc. in Q1 2018, an estimated $27.3M increase.
- Sarissa Capital Management's biggest Q1 2018 reduction was Achillion Pharmaceuticals, cutting an estimated $6.55M.
- Sarissa Capital Management fully exited Bioverativ Inc. Common Stock in Q1 2018, selling an estimated $62.8M.
- Sarissa Capital Management's ten largest holdings make up 100% of its $432M portfolio in Q1 2018.
- Sarissa Capital Management opened 1 new position and closed 1 in Q1 2018.
- Sarissa Capital Management's portfolio value rose 11% quarter-over-quarter to $432M.
Based on Sarissa Capital Management's 13F filing for Q1 2018, filed 15 May 2018.